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ABSTRACT
Objective: This study aimed to develop and validate an analytical method and to determine the effect of different anticoagulants for analyzing 
metformin HCl level in human plasma.
Methods: Analysis was performed with high-performance liquid chromatography method using a photodiode array detector set at 234 nm, a C18 
SunFire™ column (5 µm, 250 mm×4.6 mm), a temperature of 40°C, a mobile phase comprising 10 mM sodium dodecyl sulfate and 10 mM phosphate 
buffer in water-acetonitrile (60:40 v/v) at pH 7.0, with a flow rate of 1.0 mL/min, and atorvastatin calcium as the internal standard. Plasma 
extraction was performed through protein precipitation using human plasma (300 µL) and acetonitrile (600 µL; 1:2 v/v). The method was linear at a 
concentration range of 20.0–5000.0 ng/mL, with r>0.9998.
Results: The stability and recovery of metformin HCl in human plasma were not different between citrate with ethylenediaminetetraacetic acid 
(EDTA) and heparin with EDTA as anticoagulants. However, a significant difference in the peak area response ratio (p<0.05) was observed between 
the three anticoagulants.
Conclusion: The validation results for the three types of plasma anticoagulants met validation requirements based on the European Medicines 
Agency bioanalytical guidelines of 2011 for accuracy and precision, selectivity, calibration curve linearity, dilution integrity, carry-over, and stability.
Keywords: Anticoagulant, Citrate, Ethylenediaminetetraacetic acid, Heparin, Human plasma, Validation.
INTRODUCTION
Metformin HCl is a biguanide drug that lowers blood sugar levels by 
decreasing the production of hepatic glucose (gluconeogenesis) and 
increasing the action of insulin (stimulating glycogenesis). Metformin is 
generally used for patients with Type 2 diabetes and has been proven as 
an effective antihyperglycemic drug, thus reducing the risk of death [1]. 
Furthermore, metformin may lower plasma glucose levels by reducing 
glucose absorption from the intestine [2]. The maximum metformin 
levels in plasma (Cmax) have been reported to be 1600±380 ng/mL. 
Metformin is also used for various critical conditions; thus, it requires 
a definite response and bioequivalence (BE) tests for a copy or 
generic drugs [3,4]. BE testing is conducted using pharmacokinetic 
studies involving the determination of plasma drug levels. Therefore, 
determining metformin concentrations in human plasma are necessary 
for pharmacokinetic studies [5].
The measurement of drug concentrations in the blood, serum, or plasma 
is considered the best approach to obtain a pharmacokinetic profile 
of a given drug [6]. In pharmacokinetic studies, plasma as biological 
matrix is usually used for analysing analyte and metabolite in plasma. 
Plasma drug levels are so low that sensitive and selective measurement 
techniques are required [7]. Plasma is an often-used biological matrix 
and is obtained through blood sampling using anticoagulants. Thus, 
one of the most important factors in obtaining plasma is the type of 
anticoagulant used [8]. Anticoagulants that are frequently used in 
blood drug analysis include ethylenediaminetetraacetic acid (EDTA), 
heparin, and citrate [8,9]. The type of anticoagulant commonly used in 
Indonesia for obtaining plasma is the citrate form as citric phosphate 
dextrose adenine because it has the ability to extend the plasma storage 
time [10]. Both citrate and EDTA work by binding calcium ions for the 
prevention of protein coagulation. In contrast, heparin has mechanisms 
as an antithrombin activator [8]. These differences between the type 
of anticoagulant used during drug analysis may affect small molecules, 
metabolic profiles, and clinical parameters of the drug to be analyzed 
[9]. Indeed, the choice of anticoagulant is an important factor because 
some ions (Na+ or K+) in the plasma have anticoagulant properties 
(e.g., Na-citrate) and others such as K-EDTA can cause either the ion 
suppression or ion enhancement in analyzing analyte or metabolite, 
which may affect the matrix during analysis [11].
A bioanalysis method should be validated before analysis for the method 
to be accurate and reliable [7]. Based on the European Medicines 
Agency (EMEA) 2011, full validation is performed for each 1st-time 
analysis method or new compound drugs [12]. If an anticoagulant is 
used for analysis, then full validation should be performed using the 
same anticoagulant. For minor change conditions such as anticoagulant 
changes in an analysis method that was once validated, a partial 
validation is acceptable.
Several methods are available for analyzing metformin HCl level in the 
plasma, including high-performance liquid chromatography (HPLC), 
which is the most widely used technique for the analysis of drugs in 
biological matrices [13,14]. In general, the use of a photodiode array 
(PDA) detector provides advantages for sensitive and selective HPLC 
systems during the analysis of drugs and their metabolites in biological 
matrices [15,16]. Using these principles, various analytical methods for 
determining plasma metformin levels have been widely developed and 
accepted [5,17-20].
Research into the effects of different anticoagulants on the 
determination of metformin HCl levels in vitro using HPLC has been 
limited; however, this information is important to better understand 
the pharmacokinetics of metformin in human plasma and its analysis. 
Therefore, in this study, we developed an in vitro metformin HCl 
analytical method for human plasma, with a focus on evaluating the 
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influence of commonly used anticoagulants, such as EDTA, citrate, and 
heparin, on specific analysis parameters, such as stability, recovery, 
chromatogram interference, and peak analytical response.
METHODS
Equipment
A set of HPLC devices (Waters 2965; Separation Module) consisting 
of pumps, an autosampler, C18 columns (Waters, SunFireTM5μm; 
250 mm×4.6 mm), PDA detectors (Waters 2996) set at 234 nm 
wavelength, with data processing on a computer were used. In addition, 
other equipment used in this study included a pH meter (Eutech 
pH 510), vacuum tubes and Vacutainers with K3EDTA anticoagulant 
(Vacuette®), vacuum tubes with Li-Heparin anticoagulant (Vacuette®), 
blood collection tubes (BD Vacutainer® Beckton, Dickinson and 
Company), analytical scales (Acculab), eluent filter (Whatman), busting/
degasser (Elmasonic S60H), microcentrifuge (Spectrafuge 16M), a −80°C 
freezer (Biomedical Labtech Deep Freezer), a −20°C freezer (Biomedical 
Labtech Deep Freezer), refrigerator set to 4°C–8°C, vortex (Maxi Mix II), 
Eppendorf micropipettes (Socorex), centrifuge tubes, sample cups, blue 
tips, yellow tips, filter paper (Perkin Elmer), and various glassware.
Materials
The reagents used in this study were of analytical grade and included 
metformin HCl (United States Pharmacopeia [USP]), calcium 
atorvastatin (USP), methanol pro HPLC (Merck), orthophosphoric acid 
(Merck), acetonitrile pro HPLC (Merck), sodium dodecyl sulfate (SDS) 
(Merck), sodium dihydrogen phosphate (Merck), sodium hydroxide 
(Merck), aquabidestilata, and human plasma (Indonesian Red Cross). 
Blood samples were obtained directly from healthy subjects.
Stock solution
Standards of metformin HCl and atorvastatin calcium were each 
weighed to obtain 10 mg. The compounds were then placed into a 10-mL 
measuring flask. From this solution, 1 mL was then further diluted into 
10 mL. Water was then added to the metformin HCl solution, while 
methanol was added to the calcium atorvastatin solution to prepare 
test concentrations of the stock solution.
Optimization of chromatographic conditions
The analysis was conducted using HPLC equipped with 
detector PDA at wavelength (λ) 234 nm, C18 column 
(Waters, SunFire™ 5 μm; 250 mm×4.6 mm). 10 mM SDS and 10 mM 
phosphate buffer in water-acetonitrile (60:40) were used as the mobile 
phase, and was adjusted to pH 7.0 with 98% orthophosphoric acid. The 
column temperature was set to 40°C. The flow rate was adjusted from 
0.8 mL/min to 1.0 mL/min over a 10-min analysis time.
System suitability test
A mixture of 10 mg μg/mL of metformin HCl and 10 μg/mL of calcium 
atorvastatin was injected as 50 μL into a HPLC equipped with PDA 
detector instrument at a wavelength of 234 nm. The injection results 
were recorded and counted for the coefficient of variation (% CV) of the 
5 times injection. The recorded parameters included the area and peak 
retention time.
Sample preparation
Sample preparation of metformin HCl in plasma was performed 
by protein precipitation. A 300-μL aliquot of plasma containing a 
concentration of metformin HCl was added to the sample cup, and 
50.0 μL of standard calcium atorvastatin 10 μg/mL was added. 600 μL 
acetonitrile was then added as a protein precipitator. The mixture was 
vortexed for 3 min to extract the metformin HCl from the plasma. The 
mixture was then centrifuged to precipitate proteins at 13,000 rpm for 
10 min. Aliquots of 1000 μL were centrifuged and transferred into vials. 
Aliquot (50.0 μL) was then injected into the HPLC system.
Validation of bioanalysis methods
In this study, the validation of the metformin HCl method in plasma 
was performed with the use of different types of anticoagulants: 
Citrate, EDTA, and heparin. Full validation was performed using plasma 
with the citrate anticoagulant and monitored for selectivity, carry-
over parameters, lowest quantity limit measurement (lower limit of 
quantification [LLOQ]), linearity of the calibration curve, accuracy, 
precision and recovery, dilution integrity, and stability. Partial validation 
was performed using EDTA and heparin for the plasma, with minimum 
parameters of accuracy and precision. However, in this study, we also 
performed recovery and stability tests on plasma EDTA and heparin to 
determine the influence of the type of anticoagulant used. Validation of 
the analytical methods was evaluated according to the EMEA guidelines 
2011 for the validation of bioanalysis methods.
RESULTS AND DISCUSSION
Optimization of conditions for the analysis method
The analysis method we used in this study was based on an HPLC method. 
The analysis conditions used C18 column (Waters, SunFire™ 5 μm; 
250 mm×4.6 mm). In addition, 10 mM SDS and 10 mM phosphate 
buffer in water-acetonitrile (60:40). The mobile phase was adjusted to 
pH 7.0 with 98% orthophosphoric acid, the column temperature was 
set to 40°C, with a flow rate of 1.0 mL/min over a 10-min analysis time. 
Calcium atorvastatin was selected as an internal standard due to its 
similar physicochemical properties, including pKa value. The analytical 
conditions resulted in the good separation of the targeted compound. 
The retention time of metformin hydrochloride was 5.4081 min and 
that of calcium atorvastatin was 7.021 min (Fig. 1). The runtime was 
quite short at 10 min, which was considered as an optimum condition.
System suitability test
CV requirements should be <2.0%. The results obtained from each 
system suitability test consistently yielded CV values <2.0%. In addition 
to CV, tailing factor was close to 1 (1.698), N (theoretical plates) was 
high and height equivalent to the theoretical plate (HETP) values 
were close to zero. Our results indicated that the N (theoretical plate) 
was 2698.88 and the HETP value was 0.0092. The analysis time for 
each injection was 10 min. The system suitability test was performed 
every time to perform the analysis on a daily basis and to confirm the 
parameters met the requirements of the validation process.
Based on the results of the optimization of the centrifugation time, 
we obtained the highest area under curve of metformin HCl with a 
centrifugation time of 10 min at a speed of 13,000 rpm with an area of 
115,432. Therefore, the extraction conditions were considered optimal 
for extracting the analytes from plasma for the types of anticoagulants 
used (plasma citrate, plasma heparin, and EDTA plasma).
Validation of bioanalysis methods
LLOQ (citrate plasma)
In this study, the measurement of the LLOQ value was performed by 
creating an analytical calibration curve with range concentration of 
20.0–5000 ng/mL. In this process, the concentration of 20.0 ng/mL 
becomes the temporary limit of LLOQ, and the replication is carried 
out for 5 times. The values of percentage difference and CV at a 
Fig. 1: Chromatogram of the system suitability test. Optimization 
of sample preparation
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concentration of 20.0 ng/mL still met the requirement of not more than 
20%; thus, the concentration met the criteria of accuracy and precision.
Selectivity test (citrate plasma)
In this study, we get the percentage difference values of LLOQ is 
3.11–19.77%, which still fulfilled the requirement (<±20%) and yielded 
a coefficient of 4.05%. In addition, at the time of analysis, the retention 
and standard plasma chromatogram for the blank showed some 
interference, but this is not significant. Interference for metformin 
HCl was 2.36–2.61% and for calcium atorvastatin it was 0.02–0.04%, 
indicating the method used in this study met the selective criteria.
Calibration curve (citrate plasma, heparin, and EDTA)
Calibration curve analysis was performed regarding the linearity 
parameter (r>0.9990), accuracy (% difference) >±15%, with the 
exception of that the LLOQ concentration should <±20%. The 
calibration curve for plasma citrate yielded a linear regression equation 
of y=0.0016+0.0002x, with r=0.9999. The heparin plasma calibration 
curve yielded a linear regression equation of y=0.0041+0.0002x, with 
r=0.9996. The EDTA calibration curve yielded a linear regression 
equation of y=0.0022+0.0002x, with r=0.9995, where x is the 
concentration of metformin HCl (μg/mL) and y is peak area ratio (PAR) 
between the response of the analyte area and the inner standard.
Test accuracy, precision (citrate plasma, heparin, and EDTA)
For the measurement of accuracy using plasma citrate, we obtained 
a percentage difference value with the range of +5.85–+18.93% for 
the LLOQ concentration and a range of −14.67–14.31% for the QC 
concentration. For the measurement of intraday precision using plasma 
citrate, we obtained a CV value <4.65% for the LLOQ concentration and 
<8.56% for QC samples. For the precision interday values, we obtained 
a CV value of <7.97% for both the LLOQ and QC. Both intraday and 
interday accuracy and precision values still met the requirements for 
the LLOQ <±20% and QC samples <±15%. In measuring the accuracy 
of heparin plasma, the values of the percentage difference ranged from 
−15.26% to + 10.50% for the LLOQ concentration, and ranged from 
−14.64% to +13.88% for plasma QC. The measurement of the intraday 
precision for heparin plasma obtained a CV value <9.50% for the 
LLOQ and QC concentrations. For the precision interday evaluation in 
plasma heparin, we obtained a CV value <8.46% for both LLOQ and QC 
concentrations. For the measurement of accuracy in plasma EDTA, we 
obtained a value of percentage difference of −15.59–+14.21% for the 
LLOQ concentration, with a range of −10.30–+14.61% for QC samples. 
For the intraday precision measurement in plasma EDTA, we obtained 
CV values <11.24% for LLOQ concentrations and QC samples. For the 
precision interday values, we obtained CV values <11.37% for both 
LLOQ concentrations and QC samples.
Dilution integrity test (plasma citrate)
To perform the dilution integrity test, we made an analyte solution in 
plasma with the concentration exceeding the LLOQ, which was equal to 
7500.0 ng/L. We then diluted this solution by a of ½ and ¼. The results 
of the dilution were tested for accuracy and precision, both for intraday 
and interday parameters. The values of the % diff were −4.34–7.63% 
for dilution ½ times and percentage difference of −5.86–11.55% for 
dilution ¼ times. As for the value of the intraday variation coefficient 
(KV), we obtained a value of <7.53% with the interday KV value <3.08% 
for both the dilution ½ and ¼ times. The accuracy and precision values 
of the dilution still fulfilled the precise criteria; thus, the dilution 
described in this study was considered validated.
Carry-over (plasma sitrat)
In this study, the percentage of followings for the analyte was 8.10%, 
while for the standard it was 0.03%. The percentage of the follow-up 
still met the requirements for analytes at <20%, while for standards it 
is <5%. This indicates that, during the analysis process, there was no 
meaningful carry-over between injections.
Stability test of metformin HCl and calcium atorvastatin stock 
solution
The results of the stability test in this study indicated a value of 
percentage difference for metformin stock solution HCl and calcium 
atorvastatin for 24 h at room temperature of −0.75–−0.16%, with a 
value of percentage difference of −1.78–0.20% after 3 days storage. 
Therefore, the standard analytical and raw stock solutions used for 
24 h and stored at room temperature were stable for at least 31 days 
in storage at 4°C.
Comparison of chromatograms of plasma citrate, heparin, and 
EDTA
There were no significant differences between the three chromatogram 
forms. We did observe some interference with plasma citrate at the 
4-min retention time, but this did not interfere with the analytical 
process (Fig. 2).
Comparison of metformin HCl stability in plasma citrate, heparin, 
and EDTA
To compare the stability of metformin HCl using different anticoagulants, 
including citrate, heparin, and EDTA, we determined if each stability 
test fulfilled the requirement that at both low and high concentration, 
quality control dictates percentage difference values of ±15%. 
Therefore, during the bioanalysis process, the storage of metformin HCl 
in plasma citrate, heparin, and EDTA in the analysis room was still stable 
for 31 days and can be used for the analysis process at −20°C–−80°C.
Comparison of the peak analytical response of plasma citrate, 
heparin, and EDTA
Given the different characteristics of anticoagulants, including differing 
physicochemical properties, plasma pH, and ionic strength, it is 
necessary to observe the chromatogram form and peak area response 
generated by the analyte and the standard with each anticoagulant type. 
In this study, we compared the PAR at the concentrations of Quality 
Control Low (QCL), Quality Control Medium (QCM) and Quality Control 
High (QCH) in each plasma sample. The analysis was done statistically 
to observe any differences. Based on the statistical analysis of PAR for 
each plasma sample, we obtained a p<0.05 (Kruskal–Wallis), which 
was good for the concentrations of QCL, QCM, and QCH. Therefore, the 
hypothesis that there is no significant difference was rejected because 
the p value we obtained was <0.05, indicating a significant difference 
between the PAR values generated from plasma citrate, heparin, and 
EDTA.
Comparison of the absolute recovery value and the modified 
recovery with plasma citrate, heparin, and EDTA
In the comparative analysis of modified recovery values using the 
plasma matrix as a comparison (not the standard solution, which is 
used for the absolute recovery), we obtained statistical results for QCL 
Fig. 2: Overlay chromatogram of plasma citrate blanks, heparin, 
and ethylenediaminetetraacetic acid
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and QCH concentrations at p=0.602 and p=0.129, respectively. Since 
p>0.05 (ANOVA, least significant difference post hoc), the hypothesis 
was accepted, indicating no significant difference in recovery between 
plasma citrate, heparin, and EDTA.
CONCLUSION
The method developed in this study to analyze plasma concentrations 
of metformin HCl using HPLC obtained an LLOQ of 20 ng/mL. The 
validation results for the three types of plasma anticoagulants met 
validation requirements based on the EMEA bioanalytical guidelines of 
2011 for accuracy and precision, selectivity, calibration curve linearity, 
dilution integrity, carry-over, and stability.
Based on the comparison of several analytical parameters, there were 
no significant differences for plasma with citrate, heparin, or EDTA 
anticoagulants regarding stability and recovery of metformin HCl in 
plasma (p>0.05, ANOVA). However, for the peak plasma response ratio 
of metformin HCl with the plasma anticoagulants citrate, heparin, and 
EDTA, a significant difference (p<0.05) was observed between plasma 
with the anticoagulant citrate-EDTA and plasma with the heparin-EDTA 
anticoagulant for low, moderate, and high concentrations. In the plasma 
blast chromatogram with citrate anticoagulant, there was considerable 
interference of plasma at a retention time <5 min, whereas in plasma 
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